Stockreport

New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Pharma’s TransCon™ PTH through Week 110 in the PaTH Forward Trial Presented at ASBMR 2022

Ascendis Pharma A/S - American Depositary Shares  (ASND) 
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ascendispharma.com
PDF -  Durability of response to TransCon PTH therapy through Week 110 demonstrated by continued normalization of serum calcium and 93% achieving independence from conventio [Read more]